Date: 2013-10-16
Type of information: Fundraising
Company: Theravectys (France)
Investors: Tethys (France), Financière IDAT (France), FGP Capital (France), other private investors
Amount: €14.7 million
Funding type: financing round
Planned used: This new financing round should enable Theravectys to speed up the development of its vaccines platform and implement international collaborations.
Others: * On October 16, 2013, Theravectys, a French biotechnology company specialized in developing vaccines using lentiviral vector technology, has announced the finalisation of a €14.7 million financing round (US$20 million).
This financing round was completed by Tethys, the holding company owned by the Bettencourt family, alongside Financière IDAT (Philippe Oddo), FGP Capital and other private investors. \" This newly raised capital will allow Theravectys to become a leader in the fields of vaccination and immunotherapy. It will enable the company to pursue the clinical development of its therapeutic anti-HIV vaccine, bring an oncology vaccine candidate to clinical trial by 2015 and help in setting up strategic partnerships with pharmaceutical firms\", says Jean-Pierre Kinet, chairman of the Theravectys Board of Directors.
A phase I/II clinical trial of a therapeutic anti-HIV vaccine is currently under way.
Therapeutic area: Infectious diseases
